Full Press Release Details
STAAR Surgical Reports Second Quarter 2020 Results
LAKE FOREST, CA, August 5, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 3, 2020.
Second Quarter 2020 Overview
"The outlook we provided in May accurately assessed the market dynamics and STAAR's ability to perform well in the midst of a prolonged shutdown of elective surgeries in most of the global markets we serve. While refractive procedures were down significantly or came to a halt in April and May in much of North America, Europe, Latin America, India and the Middle East, continuing recovery and growth were recorded in Japan, Korea and China. In June, ICL implant procedures recorded strong year-over-year growth with units up 65% in Japan, 24% in Rest of Asia Pacific, 17% in Germany, 15% in Distributor Markets in Europe and 11% in Korea. The positive trending continued in July with China experiencing stronger than anticipated demand as the peak season began in earnest. While COVID-19 hotspots and government public health mandates may reoccur moving forward, we anticipate less business interruption and continued increased interest in our EVO ICL lens-based refractive solutions in Q3 and Q4. Our team is squarely focused on generating significant growth by supporting our surgeon partners as they restart their practices with patient recruiting programs, training and digital marketing," said Caren Mason, President and CEO of STAAR Surgical.
"During Q3, we plan to launch the European commercialization of our innovative EVO Viva presbyopia-correcting lens. We will begin our phased rollout of the EVO Viva lens to select surgeons in early September. We are also anticipating completing enrollment in our U.S. EVO clinical trial in the September timeframe," concluded Ms. Mason.
Financial Overview - Q2 2020
Net sales were $35.2 million for the second quarter of 2020, down 11% compared to $39.7 million reported in the prior year quarter. The sales decrease was driven by ICL revenue and unit growth declines of 11% and 3%, respectively, as compared to the prior year period. Other Product Sales decreased 15% compared to the prior year quarter. ICL revenue was 87% of total Net sales for the second quarter of 2020.
Gross profit margin for the second quarter of 2020, was 69.4% compared to the prior year period of 75.4%. The decrease in gross margin is primarily attributable to geographic sales mix and a voluntary six-week COVID-19 related manufacturing pause that ended on April 27, 2020. Excluding the manufacturing pause related expenses from the second quarter of 2020 gross profit margin would have been 72.2%.
Operating expenses for the second quarter were $25.5 million compared to the prior year quarter of $25.3 million. General and administrative expenses were $7.8 million compared to the prior year quarter of $7.5 million. The increase in general and administrative expenses was due to increased headcount and salary-related expenses, partially offset by a decrease in variable compensation and travel expenses. Marketing and selling expenses were $10.3 million compared to the prior year quarter of $11.7 million. The decrease in marketing and selling expenses is due to decreased trade show expenses and travel expenses, partially offset by increased advertising and promotional activities. Research and development expenses were $7.3 million compared to the prior year quarter of $6.1 million. The increase in research and development expenses was due to increased clinical expenses associated with our EVO clinical trial in the U.S., and increased headcount and salary-related expenses, partially offset by variable compensation and travel expense.
Net loss for the second quarter of 2020 was ($1.2) million or approximately ($0.03) per diluted share compared with net income of $3.9 million or $0.08 per diluted share for the prior year quarter. Adjusted Net Income for the second quarter of 2020 was $1.4 million or $0.03 per diluted share compared to $6.5 million or $0.14 per diluted share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.
Cash and cash equivalents at July 3, 2020 totaled $116.3 million, compared to $120.0 million at the end of fiscal 2019. The Company had $1.3 million drawn on its line of credit in Japan and no other debt at July 3, 2020. During the second quarter of 2020, the Company achieved breakeven cash from operations and invested $2.0 million in property and equipment.
The Company will host a conference call and webcast today, Wednesday, August 5 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 9428649), please dial 833-350-1429 for domestic participants and 647-689-6661 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
A taped replay of the conference call (Conference ID 9428649) will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 800-585-8367 for domestic callers and 416-621-4642 for international callers. An archived webcast will also be available at www.staar.com.
Use of Non-GAAP Financial Measures
This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. "Adjusted Net Income" and "Adjusted Net Income Per Share" exclude the following items that are included in "Net Income" as calculated in accordance with U.S. generally accepted accounting principles ("GAAP"): gain or loss on foreign currency transactions, stock-based compensation expenses, and valuation allowance adjustments. Management believes that "Adjusted Net Income" and "Adjusted Net Income per share" are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.
Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board's Accounting Standards Codification (ASC) 718. Valuation allowance adjustments can occur from time to time based on forecasted changes in operating results until all net operating loss carryforwards are fully utilized. In calculating Adjusted Net Income and Adjusted Net Income Per Share, STAAR excludes these expenses because they are non-
cash expenses and because of the considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.
The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company's results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer Lens or "ICL", which includes the EVO Visian ICL product line. More than 1,000,000 Visian ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company's website at www.staar.com.
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans, strategies, and objectives of management for 2020 or prospects for achieving such plans, expectations for sales, revenue, or earnings, the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to its impact on sales, operations or clinical trials globally), product safety or effectiveness, the status of our pipeline of ICL products with regulators, including our EVO family of lenses in the U.S., and any statements of assumptions underlying any of the foregoing, including those relating to our product pipeline and market expansion activities. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company's Quarterly Report on Form 10-Q for the quarter ended April 3, 2020, and Annual Report on Form 10-K for the year ended January 3, 2020 under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investor Information" section of the company's website under the heading "SEC Filings." We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or
improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The Visian ICL with CentraFLOW, now known as EVO Visian ICL, is not yet approved for sale in the United States.
CONTACT:Investors & Media
Vice President, Investor, Media Relations and Corporate Development
(626) 303-7902, Ext. 3023
Consolidated Balance Sheets
| ASSETS | July 3, 2020 | January 3, 2020 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 116,315 | $ | 119,968 | ||||
| Accounts receivable trade, net | 39,469 | 30,996 | ||||||
| Inventories, net | 17,836 | 17,142 | ||||||
| Prepayments, deposits, and other current assets | 8,897 | 6,560 | ||||||
| Total current assets | 182,517 | 174,666 | ||||||
| Property, plant, and equipment, net | 21,478 | 17,065 | ||||||
| Finance lease right-of-use assets, net | 687 | 1,867 | ||||||
| Operating lease right-of-use assets, net | 5,587 | 6,684 | ||||||
| Intangible assets, net | 280 | 296 | ||||||
| Goodwill | 1,785 | 1,786 | ||||||
| Deferred income taxes | 5,114 | 3,750 | ||||||
| Other assets | 591 | 751 | ||||||
| Total assets | $ | 218,039 | $ | 206,865 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Line of credit | $ | 1,325 | $ | 1,827 | ||||
| Accounts payable | 8,890 | 8,050 | ||||||
| Obligations under finance leases | 493 | 560 | ||||||
| Obligations under operating leases | 2,355 | 2,700 | ||||||
| Allowance for sales returns | 4,285 | 3,644 | ||||||
| Other current liabilities | 14,241 | 17,697 | ||||||
| Total current liabilities | 31,589 | 34,478 | ||||||
| Obligations under finance leases | 108 | 366 | ||||||
| Obligations under operating leases | 3,320 | 4,086 | ||||||
| Asset retirement obligations | 212 | 211 | ||||||
| Pension liability | 8,136 | 7,840 | ||||||
| Total liabilities | 43,365 | 46,981 | ||||||
| Stockholders' equity: | ||||||||
| Common stock | 458 | 448 | ||||||
| Additional paid-in capital | 320,235 | 304,288 | ||||||
| Accumulated other comprehensive loss | (2,909 | ) | (3,048 | ) | ||||
| Accumulated deficit | (143,110 | ) | (141,804 | ) | ||||
| Total stockholders' equity | 174,674 | 159,884 | ||||||
| Total liabilities and stockholders' equity | $ | 218,039 | $ | 206,865 |
Consolidated Statements of Operations
(In 000's except for per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||||||||
| % of | July 3, | % of | June 28, | Fav (Unfav) | % of | July 3, | % of | June 28, | Fav (Unfav) | |||||||||||||||||||||||||||||||||||
| Sales | 2020 | Sales | 2019 | Amount | % | Sales | 2020 | Sales | 2019 | Amount | % | |||||||||||||||||||||||||||||||||
| Net sales | 100.0 | % | $ | 35,194 | 100.0 | % | $ | 39,664 | $ | (4,470 | ) | -11.3 | % | 100.0 | % | $ | 70,381 | 100.0 | % | $ | 72,247 | $ | (1,866 | ) | -2.6 | % | ||||||||||||||||||
| Cost of sales | 30.6 | % | 10,764 | 24.6 | % | 9,765 | (999 | ) | -10.2 | % | 30.1 | % | 21,191 | 25.1 | % | 18,168 | (3,023 | ) | -16.6 | % | ||||||||||||||||||||||||
| Gross profit | 69.4 | % | 24,430 | 75.4 | % | 29,899 | (5,469 | ) | -18.3 | % | 69.9 | % | 49,190 | 74.9 | % | 54,079 | (4,889 | ) | -9.0 | % | ||||||||||||||||||||||||
| Selling, general and administrative expenses: | ||||||||||||||||||||||||||||||||||||||||||||
| General and administrative | 22.3 | % | 7,848 | 18.9 | % | 7,508 | (340 | ) | -4.5 | % | 22.5 | % | 15,817 | 19.9 | % | 14,345 | (1,472 | ) | -10.3 | % | ||||||||||||||||||||||||
| Marketing and selling | 29.3 | % | 10,326 | 29.5 | % | 11,682 | 1,356 | 11.6 | % | 30.3 | % | 21,354 | 30.2 | % | 21,825 | 471 | 2.2 | % | ||||||||||||||||||||||||||
| Research and development | 20.8 | % | 7,311 | 15.4 | % | 6,098 | (1,213 | ) | -19.9 | % | 20.2 | % | 14,209 | 16.3 | % | 11,733 | (2,476 | ) | -21.1 | % | ||||||||||||||||||||||||
| Total selling, general, and administrative expenses | 72.4 | % | 25,485 | 63.8 | % | 25,288 | (197 | ) | -0.8 | % | 73.0 | % | 51,380 | 66.4 | % | 47,903 | (3,477 | ) | -7.3 | % | ||||||||||||||||||||||||
| Operating income (loss) | -3.0 | % | (1,055 | ) | 11.6 | % | 4,611 | (5,666 | ) | -122.9 | % | -3.1 | % | (2,190 | ) | 8.5 | % | 6,176 | (8,366 | ) | -135.5 | % | ||||||||||||||||||||||
| Other income (expense): | ||||||||||||||||||||||||||||||||||||||||||||
| Interest income, net | 0.1 | % | 20 | 0.7 | % | 259 | (239 | ) | -92.3 | % | 0.3 | % | 236 | 0.7 | % | 530 | (294 | ) | -55.5 | % | ||||||||||||||||||||||||
| Gain (loss) on foreign currency transactions | 1.1 | % | 388 | 0.0 | % | 11 | 377 | 3427.3 | % | -0.1 | % | (80 | ) | -0.3 | % | (237 | ) | 157 | 66.2 | % | ||||||||||||||||||||||||
| Royalty income | 0.1 | % | 52 | 0.4 | % | 163 | (111 | ) | -68.1 | % | 0.2 | % | 146 | 0.5 | % | 334 | (188 | ) | -56.3 | % | ||||||||||||||||||||||||
| Other income (expense), net | -0.1 | % | (21 | ) | 0.0 | % | 1 | (22 | ) | -2200.0 | % | 0.0 | % | (20 | ) | 0.1 | % | 98 | (118 | ) | -120.4 | % | ||||||||||||||||||||||
| Total other income, net | 1.2 | % | 439 | 1.1 | % | 434 | 5 | 1.2 | % | 0.4 | % | 282 | 1.0 | % | 725 | (443 | ) | -61.1 | % | |||||||||||||||||||||||||
| Income (loss) before provision for income taxes | -1.8 | % | (616 | ) | 12.7 | % | 5,045 | (5,661 | ) | -112.2 | % | -2.7 | % | (1,908 | ) | 9.5 | % | 6,901 | (8,809 | ) | -127.6 | % | ||||||||||||||||||||||
| Provision (benefit) for income taxes | 1.5 | % | 556 | 2.9 | % | 1,131 | 575 | 50.8 | % | -0.8 | % | (602 | ) | 2.2 | % | 1,620 | 2,222 | 137.2 | % | |||||||||||||||||||||||||
| Net income (loss) | -3.3 | % | $ | (1,172 | ) | 9.8 | % | $ | 3,914 | $ | (5,086 | ) | -129.9 | % | -1.9 | % | $ | (1,306 | ) | 7.3 | % | $ | 5,281 | $ | (6,587 | ) | -124.7 | % | ||||||||||||||||
| Net income (loss) per share - basic | $ | (0.03 | ) | $ | 0.09 | $ | (0.03 | ) | $ | 0.12 | ||||||||||||||||||||||||||||||||||
| Net income (loss) per share - diluted | $ | (0.03 | ) | $ | 0.08 | $ | (0.03 | ) | $ | 0.11 | ||||||||||||||||||||||||||||||||||
| Weighted average shares outstanding - basic | 45,354 | 44,479 | 45,152 | 44,357 | ||||||||||||||||||||||||||||||||||||||||
| Weighted average shares outstanding - diluted | 45,354 | 46,733 | 45,152 | 46,842 |
Consolidated Statements of Cash Flows
| Three Months Ended | Six Months Ended | |||||||||||||||
| July 3, 2020 | June 28, 2019 | July 3, 2020 | June 28, 2019 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net income (loss) | $ | (1,172 | ) | $ | 3,914 | $ | (1,306 | ) | $ | 5,281 | ||||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||||||||||
| Depreciation of property and equipment | 752 | 761 | 1,518 | 1,983 | ||||||||||||
| Amortization of long-lived intangibles | 8 | 9 | 17 | 17 | ||||||||||||
| Deferred income taxes | - | 314 | (1,369 | ) | 393 | |||||||||||
| Change in net pension liability | 203 | 84 | 376 | 203 | ||||||||||||
| Stock-based compensation expense | 2,918 | 2,579 | 5,839 | 5,220 | ||||||||||||
| Loss on disposal of property and equipment | - | - | 3 | - | ||||||||||||
| Provision for sales returns and bad debts | 525 | 2 | 605 | (32 | ) | |||||||||||
| Inventory provision | 480 | 332 | 816 | 787 | ||||||||||||
| Changes in working capital: | ||||||||||||||||
| Accounts receivable | (4,947 | ) | (5,979 | ) | (8,409 | ) | (6,533 | ) | ||||||||
| Inventories | (441 | ) | 113 | (932 | ) | 106 | ||||||||||
| Prepayments, deposits and other current assets | 274 | 1,163 | (2,172 | ) | (1,154 | ) | ||||||||||
| Accounts payable | (610 | ) | 748 | 297 | 563 | |||||||||||
| Other current liabilities | 1,993 | (563 | ) | (3,471 | ) | (2,626 | ) | |||||||||
| Net cash provided by (used in) operating activities | (17 | ) | 3,477 | (8,188 | ) | 4,208 | ||||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Acquisition of property and equipment | (2,025 | ) | (2,398 | ) | (4,210 | ) | (4,601 | ) | ||||||||
| Increase in patents and licenses | - | - | - | (30 | ) | |||||||||||
| Net cash used in investing activities | (2,025 | ) | (2,398 | ) | (4,210 | ) | (4,631 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Repayment on line of credit | (3 | ) | (500 | ) | (508 | ) | (999 | ) | ||||||||
| Repayment of finance lease obligations | (110 | ) | (316 | ) | (346 | ) | (681 | ) | ||||||||
| Proceeds from vested resricted stock and exercise of stock options | 7,553 | 488 | 9,558 | 1,112 | ||||||||||||
| Net cash provided by (used in) financing activities | 7,440 | (328 | ) | 8,704 | (568 | ) | ||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 66 | 267 | 41 | 243 | ||||||||||||
| Increase (decrease) in cash and cash equivalents | 5,464 | 1,018 | (3,653 | ) | (748 | ) | ||||||||||
| Cash, cash equivalents and restricted cash, at beginning of the period | 110,851 | 102,233 | 119,968 | 103,999 | ||||||||||||
| Cash, cash equivalents and restricted cash, at end of the period | $ | 116,315 | $ | 103,251 | $ | 116,315 | $ | 103,251 |
Reconciliation of Non-GAAP Financial Measure
Adjusted Net Income (Loss) and Net Income (Loss) Per Share
| Three Months Ended | Six Months Ended | |||||||||||||
| July 3, 2020 | June 28, 2019 | July 3, 2020 | June 28, 2019 | |||||||||||
| Net income (loss) (as reported) | $ | (1,172 | ) | $ | 3,914 | $ | (1,306 | ) | $ | 5,281 | ||||
| Less: | ||||||||||||||
| Foreign currency impact | (388 | ) | (11 | ) | 80 | 237 | ||||||||
| Stock-based compensation expense | 2,918 | 2,579 | 5,839 | 5,220 | ||||||||||
| Valuation allowance adjustment | - | - | (1,369 | ) | - | |||||||||
| Net income (adjusted) | $ | 1,358 | $ | 6,482 | $ | 3,244 | $ | 10,738 | ||||||
| Net income (loss) per share, basic (as reported) | $ | (0.03 | ) | $ | 0.09 | $ | (0.03 | ) | $ | 0.12 | ||||
| Foreign currency impact | - | - | - | - | ||||||||||
| Stock-based compensation expense | 0.06 | 0.06 | 0.13 | 0.12 | ||||||||||
| Valuation allowance adjustment | - | - | (0.03 | ) | - | |||||||||
| Net income per share, basic (adjusted) | $ | 0.03 | $ | 0.15 | $ | 0.07 | $ | 0.24 | ||||||
| Net income (loss) per share, diluted (as reported) | $ | (0.03 | ) | $ | 0.08 | $ | (0.03 | ) | $ | 0.11 | ||||
| Foreign currency impact | - | - | - | 0.01 | ||||||||||
| Stock-based compensation expense | 0.06 | 0.06 | 0.12 | 0.11 | ||||||||||
| Valuation allowance adjustment | - | - | (0.02 | ) | - | |||||||||
| Net income per share, diluted (adjusted) | $ | 0.03 | $ | 0.14 | $ | 0.07 | $ | 0.23 | ||||||
| Weighted average shares outstanding - Basic | 45,354 | 44,479 | 45,152 | 44,357 | ||||||||||
| Weighted average shares outstanding - Diluted | 47,546 | 46,733 | 47,328 | 46,842 |
Note: Net income per share (adjusted), basic and diluted, may not add due to rounding
STAAR Surgical Company
Reconciliation of Non-GAAP Financial Measure
Constant Currency Sales
| Three Months Ended | |||||||||||||||||||||||||||
| July 3, | Effect of | Constant | June 28, | As Reported | Constant Currency | ||||||||||||||||||||||
| Sales | 2020 | Currency | Currency | 2019 | $ Change | % Change | $ Change | % Change | |||||||||||||||||||
| ICL | $ | 30,728 | $ | (6 | ) | $ | 30,722 | $ | 34,432 | $ | (3,704 | ) | -10.8 | % | $ | (3,710 | ) | -10.8 | % | ||||||||
| IOL | 2,561 | (41 | ) | 2,520 | 3,874 | (1,313 | ) | -33.9 | % | (1,354 | ) | -35.0 | % | ||||||||||||||
| Other | 1,905 | (67 | ) | 1,838 | 1,358 | 547 | 40.3 | % | 480 | 35.3 | % | ||||||||||||||||
| Other Products | 4,466 | (108 | ) | 4,358 | 5,232 | (766 | ) | -14.6 | % | (874 | ) | -16.7 | % | ||||||||||||||
| Total Sales | $ | 35,194 | $ | (114 | ) | $ | 35,080 | $ | 39,664 | $ | (4,470 | ) | -11.3 | % | $ | (4,584 | ) | -11.6 | % | ||||||||
| Six Months Ended | |||||||||||||||||||||||||||
| July 3, | Effect of | Constant | June 28, | As Reported | Constant Currency | ||||||||||||||||||||||
| Sales | 2020 | Currency | Currency | 2019 | $ Change | % Change | $ Change | % Change | |||||||||||||||||||
| ICL | $ | 60,068 | $ | 95 | $ | 60,163 | $ | 62,218 | $ | (2,150 | ) | -3.5 | % | $ | (2,055 | ) | -3.3 | % | |||||||||
| IOL | 6,555 | (41 | ) | 6,514 | 7,891 | (1,336 | ) | -16.9 | % | (1,377 | ) | -17.5 | % | ||||||||||||||
| Other | 3,758 | (67 | ) | 3,691 | 2,138 | 1,620 | 75.8 | % | 1,553 | 72.6 | % | ||||||||||||||||
| Other Products | 10,313 | (108 | ) | 10,205 | 10,029 | 284 | 2.8 | % | 176 | 1.8 | % | ||||||||||||||||
| Total Sales | $ | 70,381 | $ | (13 | ) | $ | 70,368 | $ | 72,247 | $ | (1,866 | ) | -2.6 | % | $ | (1,879 | ) | -2.6 | % |